Merck & Co Inc Stock Research

Market Summary

USD103.52-0.88

Market Closed

-0.84%

MRK Alerts

2 major insider sales recently.

MRK Stock Price

MRK RSI Chart

MRK Valuation

Market Cap

272.8B

Price/Earnings (Trailing)

17.88

Price/Sales (Trailing)

4.63

EV/EBITDA

Price/Free Cashflow

13.8

MRK Price/Sales (Trailing)

MRK Profitability

EBT Margin

27.74%

Return on Equity

31.57%

Return on Assets

13.3%

Free Cashflow Yield

7.24%

MRK Fundamentals

MRK Revenue

Revenue (TTM)

59.3B

Revenue Y/Y

2.29%

Revenue Q/Q

-7.55%

MRK Earnings

Earnings (TTM)

14.5B

Earnings Y/Y

-19.72%

Earnings Q/Q

-7.11%

Price Action

52 Week Range

77.92115.49

(Low)(High)

Last 7 days

-3.6%

Last 30 days

-5.1%

Last 90 days

-7.5%

Trailing 12 Months

32.8%

MRK Financial Health

Current Ratio

1.47

MRK Investor Care

Dividend Yield

2.7%

Dividend/Share (TTM)

2.8

Shares Dilution (1Y)

0.08%

Diluted EPS (TTM)

5.71

Peers (Alternatives to Merck)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	396.9B	94.9B	-4.42%	-11.67%	22.12	4.18	1.25%	-14.07%
LLY	298.8B	28.5B	1.30%	17.85%	47.85	10.47	0.79%	11.88%
MRK	272.8B	59.3B	-5.09%	32.83%	17.88	4.63	21.72%	11.27%
PFE	226.2B	100.3B	-5.50%	-20.78%	7.21	2.25	23.43%	42.74%
BMY	142.4B	46.2B	-5.97%	-4.10%	22.5	3.08	-0.49%	-9.54%
MID-CAP
PRGO	4.5B	4.5B	-8.55%	-11.11%	-32.05	1.01	7.56%	-104.06%
RETA	3.2B	2.2M	109.33%	133.59%	-10.15	1.4K	-80.71%	-4.88%
SMALL-CAP
SUPN	1.9B	667.2M	-10.48%	10.28%	30.48	2.77	15.09%	13.64%
TLRY	1.6B	602.5M	-5.76%	-54.20%	-2.78	2.67	18.18%	-18.59%
CGC	923.6M	478.9M	-20.83%	-73.20%	-0.29	1.93	-31.50%	-634.70%
INVA	772.8M	285.2M	-9.04%	-42.36%	3.51	2.71	-27.21%	-40.28%
CRON	726.9M	114.5M	-12.79%	-47.96%	-4.31	6.35	27.90%	57.40%
ACRS	539.5M	29.8M	-36.94%	-53.16%	-6.21	18.13	340.05%	4.35%
OCUL	379.1M	51.5M	-14.46%	-5.94%	-5.34	7.36	18.32%	-984.05%
ENDP	94.1M	2.3B	-43.99%	-88.43%	-0.03	0.04	-22.53%	-376.66%

Financials for Merck

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	0.5%	59,283	58,974	57,169	53,978	48,704
S&GA Expenses	-1.4%	10,042	10,185	10,001	9,770	9,634
R&D Expenses	5.5%	13,548	12,841	10,887	12,410	12,245
EBITDA	-2.1%	18,268	18,664	21,157	18,246	-
EBITDA Margin	-2.6%	0.31*	0.32*	0.37*	0.34*	-
Earnings Before Taxes	-2.4%	16,444	16,840	18,523	15,753	13,879
EBT Margin	-2.9%	0.28*	0.29*	0.32*	0.29*	-
Interest Expenses	4.5%	888	850	806	-	-
Net Income	-4.9%	14,519	15,260	16,579	14,180	13,049
Net Income Margin	-5.4%	0.24*	0.26*	0.29*	0.26*	-
Free Cahsflow	-3.4%	19,095	19,760	18,955	16,092	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	1.9%	109,160	107,081	107,095	106,668	105,694
Current Assets	6.4%	35,722	33,561	32,116	31,184	30,266
Cash Equivalents	13.9%	12,694	11,145	9,675	8,556	8,096
Inventory	5.3%	5,911	5,614	5,535	5,774	5,953
Net PPE	4.9%	21,422	20,424	20,059	19,747	19,279
Goodwill	0.2%	21,204	21,160	21,213	21,258	21,264
Current Liabilities	5.4%	24,239	22,998	23,168	22,316	23,872
LT Debt, Current	-	2,300	-	-	-	-
LT Debt, Non Current	0.9%	28,745	28,482	28,684	30,586	30,690
Shareholder's Equity	3.4%	45,991	44,458	43,318	40,953	38,184
Retained Earnings	1.9%	61,081	59,928	58,437	56,252	53,696
Additional Paid-In Capital	0.3%	44,379	44,243	44,115	44,275	44,238
Accumulated Depreciation	0.4%	17,985	17,921	17,798	18,498	18,192
Minority Interest	1.5%	67.00	66.00	75.00	70.00	73.00

* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-3.4%	19,095	19,760	18,955	16,643	13,122
Share Based Compensation	5.0%	541	515	493	488	479
Cashflow From Investing	67.5%	-4,960	-15,261	-15,360	-16,908	-16,421
Cashflow From Financing	-286.7%	-9,119	-2,358	-1,930	2,109	3,097
Dividend Payments	1.5%	7,012	6,905	6,807	6,710	6,610
Buy Backs	-100.0%	0.00	36.00	1,202	840	-

Risks for MRK

What is the probability of a big loss on MRK?

16.5%

Probability that Merck stock will be more than 20% underwater in next one year

Probability that Merck stock will be more than 30% underwater in next one year.

Probability that Merck stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Merck was unfortunately bought at previous high price.

Drawdowns

Returns for MRK

Cumulative Returns on MRK

12.9%

10-Year Cumulative Returns

14.1%

7-Year Cumulative Returns

18.6%

5-Year Cumulative Returns

21.3%

3-Year Cumulative Returns

What are the long-term rolling returns for MRK?

FIve years rolling returns for Merck.

Annualized Returns

Which funds bought or sold MRK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-15	B. Riley Wealth Advisors, Inc.	added	0.12	4,918,200	21,436,200	0.60%
2023-03-13	Claro Advisors LLC	added	30.13	439,275	1,192,280	0.39%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-2.09	89,259,000	430,663,000	0.47%
2023-03-10	BAILLIE GIFFORD & CO	unchanged	-	3,421	16,421	-%
2023-03-10	MATHER GROUP, LLC.	added	3.46	765,244	3,065,240	0.06%
2023-03-08	SHEETS SMITH WEALTH MANAGEMENT	reduced	-0.43	586,661	2,660,660	0.42%
2023-03-08	Capital Asset Advisory Services LLC	added	1.33	593,991	2,345,990	0.19%
2023-03-07	Great Lakes Retirement, Inc.	new	-	565,897	565,897	0.14%
2023-03-06	BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL	reduced	-2.95	1,153,190	5,758,190	2.19%
2023-03-06	NORTH STAR ASSET MANAGEMENT INC	added	14.45	458,334	1,423,330	0.09%

Latest Funds Activity

Are funds buying MRK calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own MRK

No. of Funds

MRK Alerts

2 major insider sales recently.

Merck News

Schedule 13G FIlings of Merck

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	8.96%	227,205,978	SC 13G/A
Feb 03, 2023	blackrock inc.	8.5%	215,011,385	SC 13G/A
Feb 09, 2022	vanguard group inc	8.36%	211,202,531	SC 13G/A
Feb 01, 2022	blackrock inc.	7.8%	198,224,264	SC 13G/A
Feb 10, 2021	vanguard group inc	8.24%	208,410,644	SC 13G/A
Feb 05, 2021	blackrock inc.	7.8%	196,213,804	SC 13G/A
Feb 12, 2020	vanguard group inc	8.26%	210,542,333	SC 13G/A
Feb 05, 2020	blackrock inc.	7.5%	190,783,225	SC 13G/A

MRK Fair Value

Recent SEC filings of Merck

View All Filings

Date Filed	Form Type	Document
Feb 24, 2023	10-K	Annual Report
Feb 16, 2023	4	Insider Trading
Feb 14, 2023	4	Insider Trading
Feb 13, 2023	4	Insider Trading
Feb 10, 2023	4	Insider Trading
Feb 09, 2023	SC 13G/A	Major Ownership Report
Feb 08, 2023	4	Insider Trading
Feb 06, 2023	4	Insider Trading
Feb 03, 2023	SC 13G/A	Major Ownership Report
Feb 02, 2023	8-K	Current Report

Latest Insider Trading transactions for MRK

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-02-15	Romanelli Joseph	sold	-541,100	108	-5,000	president, human health int?l
2023-02-13	MIZELL STEVEN	sold	-198,017	109	-1,815	evp, chief hr officer
2023-02-10	Williams David Michael	acquired	128,598	106	1,205	evp,chief info&digital officer
2023-02-10	Williams David Michael	sold (taxes)	-44,075	106	-413	evp,chief info&digital officer
2023-02-09	MIZELL STEVEN	sold	-535,006	107	-5,000	evp, chief hr officer
2023-02-06	MIZELL STEVEN	sold	-462,473	104	-4,436	evp, chief hr officer
2023-02-03	Zachary Jennifer	sold	-7,782,760	103	-75,436	evp, general counsel
2023-02-03	Zachary Jennifer	acquired	4,227,430	56.04	75,436	evp, general counsel
2023-01-23	Davis Robert M	acquired	2,661,730	109	24,224	ceo & president
2023-01-23	Chattopadhyay Sanat	acquired	1,922,350	109	17,495	exe v-p & pres. mmd

About Merck

MRK Income Statement

2022-12-31

Consolidated Statement of Income - USD ($) $ in Millions	12 Months Ended
Consolidated Statement of Income - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Sales	$ 59,283	$ 48,704	$ 41,518
Costs, Expenses and Other
Cost of sales	17,411	13,626	13,618
Selling, general and administrative	10,042	9,634	8,955
Research and development	13,548	12,245	13,397
Restructuring costs	337	661	575
Other (income) expense, net	1,501	(1,341)	(890)
Total costs, expenses and other	42,839	34,825	35,655
Income from Continuing Operations Before Taxes	16,444	13,879	5,863
Taxes on Income from Continuing Operations	1,918	1,521	1,340
Net Income from Continuing Operations	14,526	12,358	4,523
Less: Net Income Attributable to Noncontrolling Interests	7	13	4
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	14,519	12,345	4,519
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	0	704	2,548
Net Income Attributable to Merck & Co., Inc.	$ 14,519	$ 13,049	$ 7,067
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
Income from Continuing Operations (in dollars per share)	$ 5.73	$ 4.88	$ 1.79
Income from Discontinued Operations (in dollars per share)	0	0.28	1.01
Net Income (in dollars per share)	5.73	5.16	2.79
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
Income from Continuing Operations (in dollars per share)	5.71	4.86	1.78
Income from Discontinued Operations (in dollars per share)	0	0.28	1.00
Net Income (in dollars per share)	$ 5.71	$ 5.14	$ 2.78

MRK Balance Sheet

2022-12-31

Consolidated Balance Sheet - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 12,694	$ 8,096
Short-term investments	498	0
Accounts receivable (net of allowance for doubtful accounts of $72 in 2022 and $62 in 2021)	9,450	9,230
Inventories (excludes inventories of $2,938 in 2022 and $2,194 in 2021 classified in Other assets - see Note 8)	5,911	5,953
Other current assets	7,169	6,987
Total current assets	35,722	30,266
Investments	1,015	370
Property, Plant and Equipment (at cost)
Land	295	326
Buildings	13,166	12,529
Machinery, equipment and office furnishings	16,760	16,303
Construction in progress	9,186	8,313
Property, plant and equipment (at cost)	39,407	37,471
Less: accumulated depreciation	17,985	18,192
Property, plant and equipment, net	21,422	19,279
Goodwill	21,204	21,264
Other Intangibles, Net	20,269	22,933
Other Assets	9,528	11,582
Total Assets	109,160	105,694
Current Liabilities
Loans payable and current portion of long-term debt	1,946	2,412
Trade accounts payable	4,264	4,609
Accrued and other current liabilities	14,159	13,859
Income taxes payable	1,986	1,224
Dividends payable	1,884	1,768
Total current liabilities	24,239	23,872
Long-Term Debt	28,745	30,690
Deferred Income Taxes	1,795	3,441
Other Noncurrent Liabilities	8,323	9,434
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021	1,788	1,788
Other paid-in capital	44,379	44,238
Retained earnings	61,081	53,696
Accumulated other comprehensive loss	(4,768)	(4,429)
Stockholders' equity before deduction for treasury stock	102,480	95,293
Less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 2021	56,489	57,109
Total Merck & Co., Inc. stockholders’ equity	45,991	38,184
Noncontrolling Interests	67	73
Total equity	46,058	38,257
Total Liabilities and Equity	$ 109,160	$ 105,694